Climb Biotherapeutics, Inc. (CLYM) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Climb Biotherapeutics, Inc. (CLYM:NASDAQ), powered by AI.

Current Price
$11.44
P/E Ratio
-9.1
Market Cap
546M
Sector
Healthcare
What is the Climb Biotherapeutics, Inc. stock price forecast?

Climb Biotherapeutics, Inc. is currently trading at $11.44. View real-time AI analysis on Alpha Lenz.

What is Climb Biotherapeutics, Inc. insider trading activity?

View the latest insider trading data for Climb Biotherapeutics, Inc. on Alpha Lenz.

What is Climb Biotherapeutics, Inc.'s P/E ratio?

Climb Biotherapeutics, Inc.'s P/E ratio is -9.1.

Climb Biotherapeutics, Inc.

NASDAQ · CLYM
$11.44+0.53(+4.86%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Climb Biotherapeutics, Inc.'s future dividend policy...
Alpha Chat Insight

Climb Biotherapeutics, Inc. trades at a P/E of -9.1 (undervalued) with modest ROE of -32.1%.

Ask for details

Company Overview

Climb Biotherapeutics, Inc. is a company in the biotechnology industry, focusing on the development and commercialization of novel therapeutic solutions. Primarily, it plays a role in advancing treatments for conditions that lack efficient medical solutions, positioning itself at the forefront of innovation in health care. The company's research and product pipeline frequently encompasses diverse therapeutic areas, leveraging cutting-edge technology and research methodologies to target complex biological processes. Climb Biotherapeutics impacts sectors such as pharmaceuticals, medical research, and health services, contributing vital new approaches that could transform patient care standards. Within the financial markets, it holds significance as a biotech entity potentially providing new breakthroughs that may influence industry standards and economic evaluations. By aiming to tackle unmet medical needs, Climb Biotherapeutics is a key player in potentially altering disease management protocols and enhancing health outcomes, thus maintaining a critical role in both the scientific community and the financial ecosystem where health innovation is a focal point of interest.

CEODr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
SectorHealthcare
IndustryBiotechnology
Employees17

Company Statistics

FY 2025

Profile

$546.45MMarket Cap
$0.00Revenue
0.00Shares Out
17Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-9.13P/E
3.41P/B
N/AEV/Sales
-7.58EV/EBITDA
-10.02P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-31.10%ROA
-32.15%ROE
-35.27%ROIC

Financial Health

$35.69MCash & Cash Equivalents
$-28.42MNet Debt
4.53%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Climb Biotherapeutics, Inc. (ticker: CLYM) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 17 employees. Market cap is $546M.

The current price is $11.44 with a P/E ratio of -9.13x and P/B of 3.41x.

ROE is -32.15%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Climb Biotherapeutics, Inc. (CLYM) Stock Forecast 2026 $11.44 — Price, Financials & Analyst Targets | Alpha Lenz